ライフサイエンスコーパス: RTV

1 RTV is responsible for the adverse interactions that occ

2 and terrestrial applications namely RTV 655, RTV 615, and Sylgard 184.

3 s C virus (HCV)/HIV-coinfected patients on a RTV-boosted ATV-based (ATVr) antiretroviral regimen (300

4 ants were followed in subjects who had added RTV to their previously failed reverse transcriptase inh

5 After RTV was withdrawn, the TVR AUC(0-12) (area under the con

6 3 and 0.09 mg/dL, respectively, for COBI and RTV recipients.

7 r 95% entrapment efficiency for both LPV and RTV and stability over 8h in simulated physiological con

8 have superior antiviral activity to LPV and RTV in vitro.

9 B subjects receiving GSK3532795 and ATV +/- RTV achieved similar declines to those receiving SOC.

10 ainst subtype B (monotherapy or with ATV +/- RTV) and subtype C, and was generally well tolerated, wh

11 otease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection.

12 marate 300 mg, emtricitabine 200 mg, and ATV/RTV 300 mg/100 mg) for 28 days.

13 erapy with ritonavir-boosted atazanavir (ATV/RTV) alone is attractive because of nucleoside reverse-t

14 ned (1:1) to receive EVG/COBI/FTC/TDF or ATV/RTV+FTC/TDF plus matching placebos, administered once da

15 function tests than did those receiving ATV/RTV+FTC/TDF and had smaller median increases in fasting

16 Thirty-four subjects simplified to ATV/RTV alone, of whom 30 (88%) did not experience virologic

17 Subjects switched to ATV/RTV at entry and discontinued NRTIs after 6 weeks.

18 EVG/COBI/FTC/TDF was non-inferior to ATV/RTV+FTC/TDF for the primary outcome (316 patients [89.5%

19 udy, simplified maintenance therapy with ATV/RTV alone maintained viral suppression in most subjects

20 (353 with EVG/COBI/FTC/TDF and 355 with ATV/RTV+FTC/TDF).

21 Despite the high genetic correlation between RTV and mean reaction time, we demonstrate distinctions

22 We investigated genetic correlations between RTV and selected neuropsychological traits using linkage

23 ving the all-oral regimen of LNF 50 mg bid + RTV, and combination regimens of LNF (25 or 50 mg bid) +

24 ving the all-oral regimen of LNF 50 mg bid + RTV, and combination regimens of LNF (25 or 50 mg bid) +

25 LNF with PEG-IFNa (LNF 25 or 50 mg po bid + RTV + PEG-IFNa) (n = 12, 24 weeks).

26 with PEG-IFNalpha (LNF 25 or 50 mg po bid + RTV + PEG-IFNalpha) (n = 12, 24 weeks).

27 -oral low-dose LNF (LNF 25 or 50 mg po bid + RTV) (n = 24, 24 weeks), and combination low-dose LNF wi

28 -oral low-dose LNF (LNF 25 or 50 mg po bid + RTV) (n = 24, 24 weeks), and combination low-dose LNF wi

29 bination regimens of LNF (25 or 50 mg bid) + RTV + PEG-IFNa, respectively.

30 bination regimens of LNF (25 or 50 mg bid) + RTV + PEG-IFNalpha, respectively.

31 (LNF 75 mg by mouth [po] twice daily [bid] + RTV) (n = 19, 12 weeks); all-oral low-dose LNF (LNF 25 o

32 F >= 75 mg by mouth [po] twice daily [bid] + RTV) (n = 19, 12 weeks); all-oral low-dose LNF (LNF 25 o

33 d EVG/COBI/FTC/TDF with a ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+

34 l midline cortex is strongly related to both RTV and ADHD, both phenotypically and genetically.

35 ted with rifampicin or efavirenz followed by RTV-containing regimens.

36 Dissolution of an ASD containing RTV, ATV and lopinavir (LPV) was also investigated.

37 Coadministration with boceprevir decreased RTV AUC during a dosing interval tau (AUC(tau)) by 22%-3

38 LNF, boosted with low-dose RTV, is a promising all-oral therapy, and maximal effica

39 LNF, boosted with low-dose RTV, is a promising all-oral therapy, and maximal effica

40 -based heritability (h(2)(SNP)) estimate for RTV was 3%.

41 creased and a similar trend was observed for RTV.

42 ctive ability of a polygenic score (PGS) for RTV, calculated using PRSice and PRS-CS, and found that

43 e essential roles of human PXR and CYP3A4 in RTV hepatotoxicity, which can be applied to guide the sa

44 hrough CYP3A4-dependent pathways involved in RTV bioactivation, oxidative stress, and endoplasmic ret

45 opinavir, ritonavir and interferon beta (LPV/RTV-IFNb) is currently being evaluated in humans in the

46 ary sites, as compared to the commercial LPV/RTV tablet (Kaletra(R)) in rats.

47 Furthermore, LPV/RTV ISNP granules displayed a 2.56-fold increase in bioa

48 In contrast, prophylactic LPV/RTV-IFNb slightly reduces viral loads without impacting

49 Therapeutic LPV/RTV-IFNb improves pulmonary function but does not reduce

50 PXR was found to modulate RTV hepatotoxicity through CYP3A4-dependent pathways inv

51 or space and terrestrial applications namely RTV 655, RTV 615, and Sylgard 184.

52 of orally dosed nirmatrelvir/ritonavir (NMR/RTV).

53 SNP granules with about 16% of LPV and 4% of RTV were palatable and stable at room temperature over 6

54 erse events (10% of COBI recipients vs 7% of RTV recipients) and adverse events leading to discontinu

55 chieved in 85% of COBI recipients and 87% of RTV recipients (difference, -2.2% [95% confidence interv

56 ata from the UK Biobank to conduct a GWAS of RTV in participants of white British ancestry (n = 404,3

57 le genome-wide association studies (GWAS) of RTV and little is known about its genetic underpinnings.

58 tically related neurophysiological marker of RTV in ADHD.

59 formulation containing a 1:1 molar ratio of RTV and ATV achieved only 50% of the supersaturation att

60 dispersion containing a 1:1:1 molar ratio of RTV, ATV and LPV, the maximum concentration of each drug

61 Our aim was to evaluate the role of RTV in the bidirectional TVR and atazanavir (ATV) intera

62 se results identify genetic underpinnings of RTV, and support the use of RTV as an endophenotype for

63 underpinnings of RTV, and support the use of RTV as an endophenotype for neurological and psychiatric

64 hich can be applied to guide the safe use of RTV-containing regimens in the clinic.

65 Effect of ultraviolet radiation on RTV 655 was also investigated and compared with the effe

66 ect of TVR on ATV exposure is higher than on RTV, despite its shorter terminal half-life.

67 en event-related midline theta oscillations, RTV, and ADHD.

68 tudy (155 to PI + RTV + FTC/TDF, 156 to PI + RTV + 3TC/ABC).

69 ects were treated in this study (155 to PI + RTV + FTC/TDF, 156 to PI + RTV + 3TC/ABC).

70 und that the RTV-PGS significantly predicted RTV in independent cohorts, but that the generalisabilit

71 Ritonavir (RTV) and atazanavir (ATV) were co-formulated with polyvi

72 Ritonavir (RTV) is on the World Health Organization's List of Essen

73 bserved when telaprevir (TVR) and ritonavir (RTV)-boosted human immunodeficiency virus (HIV) protease

74 al (ARV) pharmacokinetic boosters ritonavir (RTV) or cobicistat (COBI) may be complicated by pharmaco

75 istance to the protease inhibitor ritonavir (RTV) in vivo.

76 mal combination regimens of LNF + ritonavir (RTV) +/- pegylated interferon alpha (PEG-IFNalpha) with

77 mal combination regimens of LNF + ritonavir (RTV) pegylated interferon alpha (PEG-IFNa) with efficacy

78 d a fixed-dose combination of LPV/ritonavir (RTV) ISNP granules, were prepared using the ISNP nanotec

79 Subjects receiving 3TC/ABC + PI + ritonavir (RTV) with HIV-1 RNA < 200 c/mL >/=3 months were randomiz

80 fficacy and safety of COBI versus ritonavir (RTV) as a pharmacoenhancer of atazanavir (ATV) in combin

81 RV) 600 mg twice daily, each with ritonavir (RTV) 100 mg on days 10-31, plus concomitant boceprevir o

82 navir (ATV) with or without (+/-) ritonavir (RTV) or standard of care (SOC) (tenofovir disoproxil fum

83 n was then fabricated from 10 mL of silicone RTV catalyst mixed with 1 mL of base and 50 mg of CaF2:E

84 were studied: (1) the plasticized PVC or SR (RTV 3140) membrane matrix without other added membrane c

85 onship between the cognitive control system, RTV, and ADHD is unknown.

86 dy drug (344 in the COBI group vs 348 in the RTV group).

87 the rate of turnover of pro variants in the RTV-treated subjects we estimated that the mean fitness

88 humanized mouse models, we recapitulated the RTV hepatotoxicity observed in the clinic.

89 using PRSice and PRS-CS, and found that the RTV-PGS significantly predicted RTV in independent cohor

90 used damage and significant discoloration to RTV 655.

91 COBI was noninferior to RTV in combination with ATV plus FTC/TDF at week 48.

92 ation capacity and reduced susceptibility to RTV.

93 Reaction time variability (RTV) is consistently increased in ADHD and is known to s

94 Reaction time variability (RTV), reflecting fluctuations in response time on cognit

95 gs compared with their coadministration with RTV.

96 Although rivaroxaban is not recommended with RTV or COBI, concomitant use was recorded in 41% of riva

97 ears old and the prevalence of DOAC use with RTV or COBI.